ADHD market seen reaching $23.8 billion by 2030

The global attention deficit hyperactivity disorder market is projected to rise from $17.38 billion in 2025 to $18.55 billion in 2026, with growth expected to continue through 2030. The outlook points to rising diagnosis, broader treatment options and faster expansion in Asia-Pacific.

Why it matters: - ADHD treatment demand is rising as awareness expands across children and adults, pushing more patients into diagnosis and care. - The market outlook signals growing opportunity for medication makers, behavioral health providers and digital mental health companies. - Long-term growth is being shaped by broader access to treatment and more personalized care models.

What happened: - The Business Research Company released its Attention Deficit Hyperactivity Disorder Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the ADHD market will grow from $17.38 billion in 2025 to $18.55 billion in 2026. - The report projects the market will reach $23.8 billion by 2030. - The report uses a 6.7% CAGR for the 2025-2026 period and a 6.4% CAGR through 2030. - The company posted a free sample of the report. - The company also provided access to the full report.

The details: - ADHD is described as a chronic neurodevelopmental condition marked by inattention, hyperactivity and impulsivity that can disrupt daily life. - ADHD is typically diagnosed in childhood, but symptoms often continue into adulthood. - Management usually combines behavioral therapy, medication and lifestyle changes. - Growth drivers include greater awareness of neurodevelopmental disorders and broader diagnostic criteria across age groups. - Wider availability of stimulant medications is also supporting demand. - The report cites rising use of behavioral therapy programs and growing recognition that ADHD persists into adulthood. - Looking ahead, demand is expected to be supported by long-acting medications, more comprehensive mental health care, telepsychiatry, digital mental health tools and research into non-stimulant treatments. - Personalized medicine is a major growth driver because treatment plans can be tailored to genetics, environment and lifestyle. - A February 2024 report from the Personalized Medicine Coalition said personalized medicines made up more than one-third of new FDA drug approvals in 2023. - The coalition said the FDA approved 16 new personalized treatments for rare diseases in 2023, compared with six in 2022, plus seven cancer drugs and three therapies for other conditions. - North America was the largest regional market in 2025 because of established healthcare infrastructure and higher diagnostic rates. - Asia-Pacific is forecast to be the fastest-growing region over the next several years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market forecast suggests ADHD care is moving beyond diagnosis alone toward longer-term management and more individualized treatment. - The emphasis on telepsychiatry and digital tools points to a broader shift in how behavioral health services are delivered. - North America’s lead reflects mature diagnosis and treatment systems, while Asia-Pacific’s faster growth points to untapped patient access and expanding care infrastructure. - The report’s mention of personalized medicine suggests ADHD is increasingly being framed as part of a wider precision-medicine market.

What's next: - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - Buyers and industry stakeholders can use the report to track regional growth, product demand and treatment shifts through 2030. - The company listed Saumya Sahay as a contact for expert inquiries, with phone and email details included in the release.